[Clinical-pharmacological studies with a new beta receptor blocking substance (LB 46, Visken)].
D000328:Adult; D003864:Depression, Chemical; D004562:Electrocardiography; D005080:Exercise Test; D006321:Heart / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007211:Indoles / Q000008:administration & dosage*; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D007545:Isoproterenol / Q000037:antagonists & inhibitors*; D011433:Propranolol / Q000627:therapeutic use; D011437:Propylamines / Q000008:administration & dosage*; D013565:Sympatholytics / Q000008:administration & dosage*; D013610:Tachycardia / Q000139:chemically induced / Q000517:prevention & control
D007211:Indoles; D011437:Propylamines; D013565:Sympatholytics; D011433:Propranolol; D007545:Isoproterenol
Klinisch-pharmakologische Untersuchungen mit einer neuen betarezeptoren-blockierenden Substanz (LB 46, Visken)